Santhera Pharmaceuticals AG Enrolls Last Patient in Pivotal US Phase III with SNT-MC17/Idebenone in Friedreich's Ataxia
11/11/2008 4:36:27 PM
Santhera Pharmaceuticals (SIX: SANN), a Swiss specialty pharmaceutical company focused on neuromuscular diseases, announced today that it has closed the recruitment for its six month pivotal Phase III trial with SNT-MC17 (INN: idebenone) in Friedreich's Ataxia in the United States. The two study centers at the Children's Hospital of Philadelphia and the School of Medicine of the University of California, Los Angeles, have enrolled a total of 70 patients. The strong support from patient advocacy groups was instrumental in considerably exceeding the original recruitment target of 51 individuals.